Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1995 May;71(5):963–968. doi: 10.1038/bjc.1995.186

Molecular design of hybrid tumour necrosis factor alpha with polyethylene glycol increases its anti-tumour potency.

Y Tsutsumi 1, T Kihira 1, S Tsunoda 1, T Kanamori 1, S Nakagawa 1, T Mayumi 1
PMCID: PMC2033790  PMID: 7734321

Abstract

This study was conducted to increase the anti-tumour potency and reduce the toxic side-effects of tumour necrosis factor alpha (TNF-alpha). Natural human TNF-alpha was chemically conjugated with monomethoxy polyethylene glycol (PEG) using succinimidyl coupling of lysine amino groups of TNF-alpha. The number-average molecular weight of PEG-modified TNF-alpha (PEG-TNF-alpha) increased with an increase in the reaction time and the initial molar ratio of PEG relative to TNF-alpha. The resulting modified TNF-alpha was separated into fractions of various molecular weights. The specific activity of separated PEG-TNF-alpha s relative to that of native TNF-alpha gradually decreased with an increase in the degree of PEG modification, but the plasma half-life was drastically increased with the increase in molecular weight of modified TNF-alpha. PEG-TNF-alpha s, in which 29% and 56% of lysine residues were coupled to PEG, had anti-tumour activity approximately 4 and 100 times greater than unmodified TNF-alpha in the murine Meth-A fibrosarcoma model. Extensive PEG modification did not increase its in vivo activity. A high dose of unmodified TNF-alpha induced toxic side-effects, but these were not observed with the modified TNF-alpha s. Optimal PEG modification of TNF-alpha markedly increased its bioavailability and may facilitate its potential anti-tumour therapeutic use.

Full text

PDF
963

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abuchowski A., Kazo G. M., Verhoest C. R., Jr, Van Es T., Kafkewitz D., Nucci M. L., Viau A. T., Davis F. F. Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycol-asparaginase conjugates. Cancer Biochem Biophys. 1984 Jun;7(2):175–186. [PubMed] [Google Scholar]
  2. Aggarwal B. B., Kohr W. J., Hass P. E., Moffat B., Spencer S. A., Henzel W. J., Bringman T. S., Nedwin G. E., Goeddel D. V., Harkins R. N. Human tumor necrosis factor. Production, purification, and characterization. J Biol Chem. 1985 Feb 25;260(4):2345–2354. [PubMed] [Google Scholar]
  3. Arakawa T., Alton N. K., Hsu Y. R. Preparation and characterization of recombinant DNA-derived human interferon-gamma. J Biol Chem. 1985 Nov 25;260(27):14435–14439. [PubMed] [Google Scholar]
  4. Blick M., Sherwin S. A., Rosenblum M., Gutterman J. Phase I study of recombinant tumor necrosis factor in cancer patients. Cancer Res. 1987 Jun 1;47(11):2986–2989. [PubMed] [Google Scholar]
  5. Carswell E. A., Old L. J., Kassel R. L., Green S., Fiore N., Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A. 1975 Sep;72(9):3666–3670. doi: 10.1073/pnas.72.9.3666. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Cavender D., Saegusa Y., Ziff M. Stimulation of endothelial cell binding of lymphocytes by tumor necrosis factor. J Immunol. 1987 Sep 15;139(6):1855–1860. [PubMed] [Google Scholar]
  7. Debs R. J., Fuchs H. J., Philip R., Brunette E. N., Düzgüneş N., Shellito J. E., Liggitt D., Patton J. R. Immunomodulatory and toxic effects of free and liposome-encapsulated tumor necrosis factor alpha in rats. Cancer Res. 1990 Jan 15;50(2):375–380. [PubMed] [Google Scholar]
  8. Gamble J. R., Harlan J. M., Klebanoff S. J., Vadas M. A. Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumor necrosis factor. Proc Natl Acad Sci U S A. 1985 Dec;82(24):8667–8671. doi: 10.1073/pnas.82.24.8667. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Goodson R. J., Katre N. V. Site-directed pegylation of recombinant interleukin-2 at its glycosylation site. Biotechnology (N Y) 1990 Apr;8(4):343–346. doi: 10.1038/nbt0490-343. [DOI] [PubMed] [Google Scholar]
  10. Haranaka K., Satomi N., Sakurai A. Antitumor activity of murine tumor necrosis factor (TNF) against transplanted murine tumors and heterotransplanted human tumors in nude mice. Int J Cancer. 1984 Aug 15;34(2):263–267. doi: 10.1002/ijc.2910340219. [DOI] [PubMed] [Google Scholar]
  11. Hershfield M. S., Chaffee S., Koro-Johnson L., Mary A., Smith A. A., Short S. A. Use of site-directed mutagenesis to enhance the epitope-shielding effect of covalent modification of proteins with polyethylene glycol. Proc Natl Acad Sci U S A. 1991 Aug 15;88(16):7185–7189. doi: 10.1073/pnas.88.16.7185. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Kamisaki Y., Wada H., Yagura T., Matsushima A., Inada Y. Reduction in immunogenicity and clearance rate of Escherichia coli L-asparaginase by modification with monomethoxypolyethylene glycol. J Pharmacol Exp Ther. 1981 Feb;216(2):410–414. [PubMed] [Google Scholar]
  13. Katre N. V., Knauf M. J., Laird W. J. Chemical modification of recombinant interleukin 2 by polyethylene glycol increases its potency in the murine Meth A sarcoma model. Proc Natl Acad Sci U S A. 1987 Mar;84(6):1487–1491. doi: 10.1073/pnas.84.6.1487. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Kimura K., Taguchi T., Urushizaki I., Ohno R., Abe O., Furue H., Hattori T., Ichihashi H., Inoguchi K., Majima H. Phase I study of recombinant human tumor necrosis factor. Cancer Chemother Pharmacol. 1987;20(3):223–229. doi: 10.1007/BF00570490. [DOI] [PubMed] [Google Scholar]
  15. Kita Y., Rohde M. F., Arakawa T., Fagin K. D., Fish E. N., Banerjee K. Characterization of a polyethylene glycol conjugate of recombinant human interferon-gamma. Drug Des Deliv. 1990 Sep;6(3):157–167. [PubMed] [Google Scholar]
  16. Knauf M. J., Bell D. P., Hirtzer P., Luo Z. P., Young J. D., Katre N. V. Relationship of effective molecular size to systemic clearance in rats of recombinant interleukin-2 chemically modified with water-soluble polymers. J Biol Chem. 1988 Oct 15;263(29):15064–15070. [PubMed] [Google Scholar]
  17. Maack T., Johnson V., Kau S. T., Figueiredo J., Sigulem D. Renal filtration, transport, and metabolism of low-molecular-weight proteins: a review. Kidney Int. 1979 Sep;16(3):251–270. doi: 10.1038/ki.1979.128. [DOI] [PubMed] [Google Scholar]
  18. Manda T., Shimomura K., Mukumoto S., Kobayashi K., Mizota T., Hirai O., Matsumoto S., Oku T., Nishigaki F., Mori J. Recombinant human tumor necrosis factor-alpha: evidence of an indirect mode of antitumor activity. Cancer Res. 1987 Jul 15;47(14):3707–3711. [PubMed] [Google Scholar]
  19. Moritz T., Niederle N., Baumann J., May D., Kurschel E., Osieka R., Kempeni J., Schlick E., Schmidt C. G. Phase I study of recombinant human tumor necrosis factor alpha in advanced malignant disease. Cancer Immunol Immunother. 1989;29(2):144–150. doi: 10.1007/BF00199290. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Nobuhara M., Kanamori T., Ashida Y., Ogino H., Horisawa Y., Nakayama K., Asami T., Iketani M., Noda K., Andoh S. The inhibition of neoplastic cell proliferation with human natural tumor necrosis factor. Jpn J Cancer Res. 1987 Feb;78(2):193–201. [PubMed] [Google Scholar]
  21. Noguchi K., Inagawa H., Tsuji Y., Morikawa A., Mizuno D., Soma G. Antitumor activity of a novel chimera tumor necrosis factor (TNF-STH) constructed by connecting rTNF-S with thymosin beta 4 against murine syngeneic tumors. J Immunother (1991) 1991 Apr;10(2):105–111. doi: 10.1097/00002371-199104000-00004. [DOI] [PubMed] [Google Scholar]
  22. Pfreundschuh M. G., Steinmetz H. T., Tüschen R., Schenk V., Diehl V., Schaadt M. Phase I study of intratumoral application of recombinant human tumor necrosis factor. Eur J Cancer Clin Oncol. 1989 Feb;25(2):379–388. doi: 10.1016/0277-5379(89)90034-5. [DOI] [PubMed] [Google Scholar]
  23. Pyatak P. S., Abuchowski A., Davis F. F. Preparation of a polyethylene glycol: superoxide dismutase adduct, and an examination of its blood circulation life and anti-inflammatory activity. Res Commun Chem Pathol Pharmacol. 1980 Jul;29(1):113–127. [PubMed] [Google Scholar]
  24. Rosenberg S. A., Grimm E. A., McGrogan M., Doyle M., Kawasaki E., Koths K., Mark D. F. Biological activity of recombinant human interleukin-2 produced in Escherichia coli. Science. 1984 Mar 30;223(4643):1412–1414. doi: 10.1126/science.6367046. [DOI] [PubMed] [Google Scholar]
  25. Rosenberg S. A., Lotze M. T., Muul L. M., Chang A. E., Avis F. P., Leitman S., Linehan W. M., Robertson C. N., Lee R. E., Rubin J. T. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987 Apr 9;316(15):889–897. doi: 10.1056/NEJM198704093161501. [DOI] [PubMed] [Google Scholar]
  26. Tamura K., Aso H., Nakamura T., Hemmi H., Ishida N. Evaluation of recombinant human tumor necrosis factor by scheduled intratumoral administration in mice bearing transplantable tumors. Tohoku J Exp Med. 1989 Feb;157(2):107–118. doi: 10.1620/tjem.157.107. [DOI] [PubMed] [Google Scholar]
  27. Van Ostade X., Tavernier J., Prangé T., Fiers W. Localization of the active site of human tumour necrosis factor (hTNF) by mutational analysis. EMBO J. 1991 Apr;10(4):827–836. doi: 10.1002/j.1460-2075.1991.tb08015.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Wadler S. The role of interferons in the treatment of solid tumors. Cancer. 1992 Aug 15;70(4 Suppl):949–958. [PubMed] [Google Scholar]
  29. Yamaoka K., Tanigawara Y., Nakagawa T., Uno T. A pharmacokinetic analysis program (multi) for microcomputer. J Pharmacobiodyn. 1981 Nov;4(11):879–885. doi: 10.1248/bpb1978.4.879. [DOI] [PubMed] [Google Scholar]
  30. Yamazaki S., Onishi E., Enami K., Natori K., Kohase M., Sakamoto H., Tanouchi M., Hayashi H. Proposal of standardized methods and reference for assaying recombinant human tumor necrosis factor. Jpn J Med Sci Biol. 1986 Jun;39(3):105–118. doi: 10.7883/yoken1952.39.105. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES